Ionis Pharmaceuticals, Inc.
IONS
$32.96
$0.060.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 705.14M | 803.07M | 813.46M | 776.62M | 787.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 705.14M | 803.07M | 813.46M | 776.62M | 787.65M |
| Cost of Revenue | 912.75M | 923.04M | 919.73M | 925.97M | 908.76M |
| Gross Profit | -207.61M | -119.98M | -106.27M | -149.35M | -121.11M |
| SG&A Expenses | 267.47M | 230.41M | 238.72M | 219.75M | 212.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.18B | 1.15B | 1.16B | 1.15B | 1.12B |
| Operating Income | -475.08M | -350.38M | -344.99M | -369.10M | -333.73M |
| Income Before Tax | -460.07M | -355.80M | -352.50M | -363.75M | -333.97M |
| Income Tax Expenses | -6.17M | 3.01M | 13.24M | 21.02M | 32.32M |
| Earnings from Continuing Operations | -453.90 | -358.81 | -365.74 | -384.77 | -366.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -453.90M | -358.81M | -365.74M | -384.77M | -366.29M |
| EBIT | -475.08M | -350.38M | -344.99M | -369.10M | -333.73M |
| EBITDA | -463.13M | -337.93M | -332.34M | -356.27M | -320.88M |
| EPS Basic | -3.04 | -2.44 | -2.53 | -2.67 | -2.56 |
| Normalized Basic EPS | -1.91 | -1.42 | -1.42 | -1.49 | -1.36 |
| EPS Diluted | -3.04 | -2.44 | -2.53 | -2.67 | -2.56 |
| Normalized Diluted EPS | -1.91 | -1.42 | -1.42 | -1.49 | -1.36 |
| Average Basic Shares Outstanding | 598.09M | 584.09M | 578.81M | 575.95M | 573.15M |
| Average Diluted Shares Outstanding | 598.09M | 584.09M | 578.81M | 575.95M | 573.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
